中国 深圳 福田区益田路6001号太平金融大厦11、12楼 邮政编码：518038 电话（Tel）：（0755） 88265288 传真（Fax）：（0755）88265537 网址（Website）：http://www.sundiallawfirm.com 广东信达律师事务所 关于深圳市信宇人科技股份有限公司 法律意见书 信达科会字（2025）第024号 致：深圳市信宇人科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司股 东会规则》（以下简称"《规则》"）等法律、法规以及现行有效的《深圳市信宇 人科技股份有限公司章程》（以下简称"《公司章程》"）的规定，广东信达律师 事务所（以下简称"信达"）接受深圳市信宇人科技股份有限公司（以下简称"公 司"）的委托，指派丛启路、冯晓雨律师（以下简称"信达律师"）出席公司2024 年年度股东大会（以下简称"本次股东大会"），在进行必要验证工作的基础上， 对本次股东大会的召集、召开程序、出席会议人员和召集人资格、表决程序和结果 等事项发表见证意见。 信达及信达律师依据《中华人民共和国证券法》《律师事务所从事证券法律业 务管理办法》和《律 ...

证券代码：688573 证券简称：信宇人 公告编号：2025-027 深圳市信宇人科技股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 19 日 （二） 股东大会召开的地点：惠州仲恺高新区东江高新科技产业园兴启西路 3 号惠州信宇人一号会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 普通股股东人数 43 普通股股东所持有表决权数量 50,984,375 例（%） 普通股股东所持有表决权数量占公司表决权数量的比例（%） 54.0702 注：截至本次股东大会股权登记日的总股本为 97,754,388 股；其中，公司回购专用账户中 股份数为 3,461,480 股，不享有股东大会表决权。 （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长杨志明先生主持，会议采用现场投 票与网络投票相 ...

中国 深圳 福田区益田路6001号太平金融大厦11、12楼 邮政编码：518038 11、12/F, TaiPing Finance Tower,Yitian Road 6001, Futian District, ShenZhen, P.R.China 518038 电话（Tel）：（0755） 88265288 传真（Fax）：（0755）88265537 网址（Website）：http://www.sundiallawfirm.com 广东信达律师事务所 关于深圳市信宇人科技股份有限公司 2024年年度股东大会之 法律意见书 信达科会字（2025）第024号 致：深圳市信宇人科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司股 东会规则》（以下简称"《规则》"）等法律、法规以及现行有效的《深圳市信宇 人科技股份有限公司章程》（以下简称"《公司章程》"）的规定，广东信达律师 事务所（以下简称"信达"）接受深圳市信宇人科技股份有限公司（以下简称"公 司"）的委托，指派丛启路、冯晓雨律师（以下简称"信达律师"）出席公司2024 年年度股东大会（以下简称"本次股东大会"），在 ...

证券代码：688573 证券简称：信宇人 公告编号：2025-027 深圳市信宇人科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 19 日 （二） 股东大会召开的地点：惠州仲恺高新区东江高新科技产业园兴启西路 3 号惠州信宇人一号会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 43 | | --- | --- | | 普通股股东人数 | 43 | | 2、出席会议的股东所持有的表决权数量 | 50,984,375 | | 普通股股东所持有表决权数量 | 50,984,375 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 54.0702 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 54.0702 ...

Core Viewpoint - The company, Xinyuren (688573), is focusing on innovation-driven differentiation in the high-end equipment manufacturing sector, particularly in lithium-ion battery drying and coating equipment, while exploring new materials and technologies for future growth [1][2][3][4]. Group 1: Competitive Advantages - The company has established a "high-end equipment + process + new materials" R&D system, emphasizing customer-oriented goals and innovation to drive competitive differentiation [2]. - The SDC coating machine features optimized airflow design and intelligent dual-chamber extrusion head, significantly enhancing coating speed, width, and stability [2]. - The company is actively exploring commercial applications of microporous substrate coating and dry coating technology in solid-state battery electrodes [2]. Group 2: Product Development and Technology - The dry electrode equipment prototype has been successfully trial-produced and is currently in parameter adjustment and technical validation stages [3]. - The dry electrode technology utilizes a "dry powder direct coating and thermal compounding" method, which simplifies the process and enhances battery performance [3]. - The Micro LED mass transfer film has achieved significant technical advancements, with properties that improve yield rates and reduce production costs, indicating strong market interest [3]. Group 3: Financial Performance - In Q1 2025, the company reported a main revenue of 54.92 million yuan, a year-on-year increase of 3.94%, while the net profit attributable to shareholders was -25.87 million yuan, an increase of 9.27% year-on-year [4]. - The company’s debt ratio stands at 63.57%, with investment income of 1.08 million yuan and financial expenses of 1.64 million yuan, resulting in a gross margin of 9.42% [4]. Group 4: Market Engagement - The company is currently expanding its order base, primarily focusing on top-tier clients, despite the ongoing structural overcapacity in the industry [3]. - The proposed human skin-like material is in the process of aligning with customer needs, although it has not yet generated revenue [4].

Core Viewpoint - The company is preparing for its 2024 Annual General Meeting (AGM), where various proposals will be discussed and voted on, including financial reports and management responsibilities [1][2][3]. Meeting Procedures - The company will verify the identity of attendees to ensure proper participation in the AGM [1]. - Shareholders must arrive 30 minutes before the meeting to complete registration and present necessary documentation [1][2]. - The meeting will follow a structured agenda, allowing shareholders to express their opinions and vote on proposals [2][3]. Proposals for Discussion - Proposal One: The 2024 Board of Directors' Work Report, detailing the company's operational performance and governance [4][5]. - Proposal Two: The 2024 Supervisory Board's Work Report, emphasizing the supervisory role in protecting shareholder interests [6]. - Proposal Three: The 2024 Financial Settlement Report, audited by a certified accounting firm, reflecting the company's financial status [7]. - Proposal Four: The 2025 Financial Budget Report, outlining the company's financial planning for the upcoming year [8]. - Proposal Five: The 2024 Annual Report and its summary, ensuring compliance with regulatory disclosure requirements [9]. - Proposal Six: The 2024 Profit Distribution Plan, based on the company's earnings and financial needs [10]. - Proposal Seven: The 2025 Director Compensation Plan, detailing the remuneration for board members [11]. - Proposal Eight: The 2025 Supervisor Compensation Plan, outlining the pay structure for supervisory board members [12]. - Proposal Nine: The 2024 Independent Director Performance Report, summarizing the independent directors' contributions [13]. - Proposal Ten: The anticipated external guarantee limit for 2025, aimed at supporting the company's operational needs [14]. - Proposal Eleven: The application for a bank loan credit limit of up to 3 billion RMB, to be used for various financing needs [15]. - Proposal Twelve: The proposal to purchase liability insurance for directors, supervisors, and senior management to mitigate operational risks [16]. Financial Performance - In 2024, the company achieved a total revenue of 621.84 million RMB, a 4.75% increase from the previous year, but reported a net loss of 63.26 million RMB, a significant decline compared to a profit in 2023 [30]. - Total assets increased by 10.41% to 2.04 billion RMB, while the net assets attributable to shareholders decreased by 12.39% to 820.31 million RMB [30].

深圳市信宇人科技股份有限公司 2024 年年度股东大会会议资料 2024 年年度股东大会 证券代码：688573 证券简称：信宇人 深圳市信宇人科技股份有限公司 ShenzhenXinyurenTechnologyCo.,Ltd. 会议资料 二〇二五年五月 深圳市信宇人科技股份有限公司 2024 年年度股东大会会议资料 | 目录 | | --- | | 2024 | 年年度股东大会会议须知 2 | | --- | --- | | 2024 | 年年度股东大会会议议程 4 | | 2024 | 年年度股东大会会议议案 6 | | | 议案一：《关于 2024 年度董事会工作报告的议案》 6 | | | 议案二：《关于 年度监事会工作报告的议案》 7 2024 | | | 议案三：《关于公司 2024 年度财务决算报告的议案》 8 | | | 议案四：《关于公司 2025 年度财务预算报告的议案》 9 | | | 议案五：《关于 年年度报告及其摘要的议案》 10 2024 | | | 议案六：《关于 2024 年度利润分配预案的议案》 11 | | | 议案七：《关于 2025 年度董事薪酬方案的议案》 12 | ...

民生证券股份有限公司 关于深圳市信宇人科技股份有限公司 2024 年度持续督导跟踪报告 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2023 年 6 月 27 日出具的《关于同意深圳市信宇人科技股份有限公司首次公开发行股票注册 的批复》（证监许可[2023]1408 号）同意注册，深圳市信宇人科技股份有限公司 （以下简称"信宇人"、"公司"）首次向社会公开发行人民币普通股（A 股） 24,438,597 股，每股发行价格为人民币 23.68 元，募集资金总额为人民币 578,705,976.96 元，扣除各类发行费用（不含增值税）人民币 72,505,761.61 元 后，实际募集资金净额为人民币 506,200,215.35 元。公司于 2023 年 8 月 17 日 在上海证券交易所科创板挂牌上市。 根据《证券发行上市保荐业务管理办法》、《上海证券交易所科创板股票上市 规则》、《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关 法律法规和规范性文件的要求，民生证券股份有限公司（以下简称"民生证券"、 "保荐机构"）作为信宇人首次公开发行股票并在科创板上市的保荐机构对信宇 人进 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 54,919,491.06, representing a 3.94% increase compared to CNY 52,838,542.99 in the same period last year[3]. - Total operating revenue for Q1 2025 was CNY 54,919,491.06, an increase of 3.9% compared to CNY 52,838,542.99 in Q1 2024[15]. - The net profit attributable to shareholders was a loss of CNY 25,865,257.17, an improvement from a loss of CNY 28,507,969.28 year-over-year[3]. - Net loss for Q1 2025 was CNY 27,583,108.21, slightly improved from a net loss of CNY 28,923,012.44 in Q1 2024, indicating a decrease in loss of 4.6%[16]. - The basic and diluted earnings per share were both negative CNY 0.27, unchanged from the previous year[3]. - The basic and diluted earnings per share for Q1 2025 were both CNY -0.27, compared to CNY -0.29 in Q1 2024, indicating a slight improvement[17]. Cash Flow - The net cash flow from operating activities was negative CNY 41,471,972.82, a significant decline of 145.38% compared to a positive cash flow of CNY 91,386,278.55 in the previous year[3][6]. - The company reported a significant drop in cash received from sales, totaling CNY 87,829,556.47 in Q1 2025, down from CNY 218,250,086.21 in Q1 2024, a decline of 59.8%[19]. - Total cash inflow from investment activities was $20 million, down from $140.01 million year-over-year[20]. - The net cash flow from financing activities was $12.27 million, recovering from a negative $8.92 million in the previous period[20]. - Cash outflows for operating activities totaled $130.98 million, slightly up from $130.82 million in the previous period[20]. - Cash inflows from financing activities amounted to $57.26 million, compared to $47.05 million in the previous period[20]. - Cash outflows for investment activities were $3.18 million, significantly lower than $185.64 million in the previous period[20]. - The company reported a decrease in cash received from other investment activities, down to $20 million from $140 million[20]. - The cash paid for purchasing goods and services was $78.46 million, an increase from $71.55 million year-over-year[20]. - The company experienced a cash flow impact from exchange rate changes of $15,091.20, slightly up from $13,758.26[20]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,112,497,960.40, reflecting a 3.44% increase from CNY 2,042,235,895.46 at the end of the previous year[3]. - The total assets increased to CNY 2,112,497,960.40 from CNY 2,042,235,895.46, marking a growth of 3.5%[13]. - The total liabilities increased to CNY 1,342,847,091.99 in the latest reporting period from CNY 1,216,992,123.45, reflecting a growth of 10.3%[13]. - The total equity attributable to shareholders decreased to CNY 766,433,185.36 from CNY 820,308,859.58, a decline of 6.6%[13]. - Current liabilities decreased from RMB 1,080,000,000 to RMB 1,050,000,000, reflecting a reduction of approximately 2.78%[12]. - The company's short-term borrowings decreased to RMB 130,003,766.66 from RMB 160,147,493.21, a decline of about 18.83%[12]. Research and Development - Research and development (R&D) expenses totaled CNY 11,779,189.93, down 40.01% from CNY 19,633,877.49 in the same period last year, with R&D expenses accounting for 21.45% of revenue, a decrease of 15.71 percentage points[3]. - Research and development expenses were CNY 11,779,189.93 in Q1 2025, down from CNY 19,633,877.49 in Q1 2024, a reduction of 40.1%[16]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 6,403[8]. - The largest shareholder, Yang Zhiming, held 29.77% of the shares, totaling 29,102,399 shares[8]. - The company has not reported any significant changes in major shareholders or their participation in margin trading activities during the reporting period[10]. Operational Status - The company is focusing on expanding its market presence and developing new technologies, although specific figures or timelines were not disclosed in the call[10]. - There are no significant reminders or alerts regarding the company's operational status during the reporting period[10].

证券代码：688573 证券简称：信宇人 公告编号：2025-026 深圳市信宇人科技股份有限公司 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 48 | | --- | --- | | 普通股股东人数 | 48 | | 2、出席会议的股东所持有的表决权数量 | 45,540,335 | | 普通股股东所持有表决权数量 | 45,540,335 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 48.2967 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 48.2967 | 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 4 月 28 日 （二） 股东大会召开的地点：惠州仲恺高新区东江高新科技产业园兴启西路 3 号惠州信宇人一号会议室 二 ...